Controlled-release naproxen compared with isoxicam in patients with osteoarthritis.

The therapeutic efficacy and tolerability of a new controlled-release 1000 mg tablet of naproxen (naproxen CR) were compared with 200 mg isoxicam in 100 out-patients with osteoarthritis. Medications were administered once daily for 4 weeks in a controlled, randomized, double-blind, parallel trial. Patients were assessed for duration of stiffness, global pain, pain in the worst affected joint, night pain, pain on full passive movement, and pain on selected activity.

[Treatment of distortions and non-traumatic conditions of pain and swelling. Double-blind trial with an analgetic and detumescent drug combination].

A combination of specifically detumescent and analgesic/antiphlogistic substances (Dolo Mobilat film tablets) was tested in a double-blind study against placebo. The active product brought about very good or good therapeutic results in approximately 78% of 50 patients suffering from distortions of joints and from painful inflammation and swelling of non-traumatic origin; the corresponding percentage obtained with the placebo was 34%. Separate evaluations of pain and swellings most relevant for their homogeneity in distortions of joints showed rates of 80% and 31%, respectively.